Compare Home Depot Inc (HD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Novartis AG — how do they compare? Home Depot Inc trades at $333.56 (market cap $332.08B), while Novartis AG trades at $156 (market cap $290.25B). The key difference: Home Depot Inc and Novartis AG are close in size by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| HD | NVS | |
|---|---|---|
Market Cap | $332.08B | $290.25B |
Sector | Consumer Cyclical | Health |
52-Week High | $423.42 | $168.62 |
52-Week Low | $297.51 | $113.50 |
Enterprise Value | $393.64B | $330.27B |
Dividend Yield | 2.8% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $338.87, down 2.63% amid bearish technical signals and mixed fundamental performance. The stock shows strong profitability with 8.41% net margin and 128.38% ROE, but faces margin compression with profit margins declining from 10.87% in 2022 to 9.28% in 2025. Recent earnings show mixed results with Q3 2025 missing expectations while Q4 2025 and Q1 2026 beat estimates. Technical analysis indicates bearish momentum with key support at $321 and resistance at $343.
Despite near-term headwinds, HD maintains strong analyst support with 59% buy ratings and $370.59 consensus target, representing 9.4% upside. The company's robust cash flow generation and Pro business growth provide long-term stability, though rising mortgage rates and housing market sensitivity pose significant risks to near-term performance.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
